No-Mortality Liver Resection for Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients

Open Access
Publisher Website
Google Scholar
Abstract
HEPATOCELLULAR carinoma (HCC) is one of the most frequently occurring tumors in humans, with more than 250,000 new cases per year diagnosed in the world.1 It generally grows in a cirrhotic liver, and its incidence in patients with this condition is 3%.2 This strict association has led some authors to consider the cirrhotic liver to be a preneoplastic condition.3 These factors, and the fact that the liver cirrhosis itself significantly reduces life expectancy, contribute to the ongoing controversy about the optimal therapeutic approaches to HCCs. The double aims of curative therapy for the tumor and the preservation of as much functioning liver parenchyma as possible are the priorities of any treatment modality for HCCs in patients with liver cirrhosis.